Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $1.9 million.

  • Tonix Pharmaceuticals Holding's Share-based Compensation rose 8526.01% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 1350.89%. This contributed to the annual value of $4.8 million for FY2024, which is 4848.52% down from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Share-based Compensation stood at $1.9 million for Q3 2025, which was up 8526.01% from $1.4 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Share-based Compensation's 5-year high stood at $2.8 million during Q1 2023, with a 5-year trough of $882000.0 in Q1 2025.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Share-based Compensation averaged around $1.7 million, with its median value being $1.7 million (2024).
  • Per our database at Business Quant, Tonix Pharmaceuticals Holding's Share-based Compensation plummeted by 5613.35% in 2024 and then surged by 8526.01% in 2025.
  • Tonix Pharmaceuticals Holding's Share-based Compensation (Quarter) stood at $2.0 million in 2023, then tumbled by 56.13% to $894000.0 in 2024, then surged by 115.1% to $1.9 million in 2025.
  • Its Share-based Compensation was $1.9 million in Q3 2025, compared to $1.4 million in Q2 2025 and $882000.0 in Q1 2025.